[1] Cossu, G., Rinaldi, R. & Colosimo, C. The rise and fall of impulse control behavior disorders. Parkinsonism & related disorders 46 Suppl 1, S24-S29, (2018).
[2] Poewe, W. et al, Lang, Parkinson disease. Nat Rev Dis Primers.. 23(3):17013. (2017).
[3] Nagatsu, T. et al, Human tyrosine hydroxylase in Parkinson's disease and in related disorders. Journal of neural transmission. 126, 397-409(1996).
[4] Fahn, S. The 200-year journey of Parkinson disease: Reflecting on the past and looking towards the future. Parkinsonism & related disorders 46 Suppl 1, S1-S5, (2018).
[5] Calabrese, V. et al, Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free radical biology & medicine. 115, 80-91 (2018).
[6] Schapira, A. H. V. Mitochondrial dysfunction in Parkinson's disease. Cell Death & Differentiation 14, 1261-1266, (2007).
[7] Bose, A. & Beal, M. F. Mitochondrial dysfunction in Parkinson's disease. J Neurochem 139, 216-231, (2016).
[8] Dias, V., Junn, E. & Mouradian, M. M. The Role of Oxidative Stress in Parkinson's Disease. Journal of Parkinson's Disease 3, 461-491, (2013).
[9] Bose, A., & Beal, M.F. Mitochondrial dysfunction in Parkinson's disease. J Neurochem. 139 Suppl 1, 216-231.(2016).
[10] Venderova, K. & Park, D.S., Programmed cell death in Parkinson's disease. Cold Spring Harbor perspectives in medicine. 2 (DOI: 10.1101/cshperspect.a009365) (2012).
[11] Hanagasi, H. A., Ayribas, D., Baysal, K. & Emre, M. Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease. International Journal of Neuroscience 115(4), 479-493, (2005).
[12] Klingelhoefer, L. & Reichmann, H. Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors. Nature Reviews Neurology 11(11), 625-636, (2015).
[13] Franco, M. R., Viana, T. F., Biscaia, S. & Bártolo, P. Levodopa Incorporation in Alginate Membranes for Drug Delivery Studies. Advanced Materials Research 749, 423-428, (2013).
[14] Kestenbaum, M. & Fahn, S. Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease. Expert opinion on drug safety 14, 761-767, (2015).
[15] Ngwuluka, N. et al. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv 7, 203-224, (2010).
[16] Nutt, J. G., et al. The On–Off Phenomenon in Parkinson's Disease. New England Journal of Medicine 310, 483-488, (1984).
[17] Ngwuluka, N., et al. Levodopa delivery systems: advancements in delivery of the gold standard. Expert Opin Drug Deliv. 7, 203-224 (2010).
[18] Poewe, W. & Antonini, A. Novel formulations and modes of delivery of levodopa. Movement Disorders 30, 114-120, (2015).
[19] El-Hattab, A.W., Zarante, A.M., Almannai, M., & Scaglia, F., Therapies for mitochondrial diseases and current clinical trials. Molecular genetics and metabolism. 122, 1-9 (2017).
[20] Li, Y., Zhao, J. & Hölscher, C. Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease. CNS drugs 31, 639-652, (2017).
[21] Xue, Z., et al, Advances in anti-Parkinson's disease drugs and their related pharmacological targets. J Int Pharm Res.. 43, 87-96. (2016).
[22] Bollimpelli, V. S., Kumar, P., Kumari, S. & Kondapi, A. K. Neuroprotective effect of curcumin-loaded lactoferrin nano particles against rotenone induced neurotoxicity. Neurochemistry international 95, 37-45, (2016).
[23] Harish, G., et al. Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: Implications for Parkinson's disease. Bioorganic & medicinal chemistry. 18, 2631-2638 (2010).
.[24] Jagatha, B., Mythri, R.B., Vali, S., & Bharath, M.M., Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free radical biology & medicine. 44, 907-917 (2008).
[25] Lee, W.H., et al. Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Current neuropharmacology. 11, 338-378 (2013).
[26] Ashley, C.E., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nature materials. 10, 389-397 (2011).
[27] Ye, Y., et al. A novel lactoferrin-modified beta-cyclodextrin nanocarrier for brain-targeting drug delivery. International journal of pharmaceutics. 458, 110-117 (2013).
[28] C, B. Physiology: Double function at the blood-brain barrier. Nature 509, 432-433, (2014).
[29] BA, F. et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America 92, 9603-9607, (1995).
[30] Kawamata T., et al. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. The American journal of pathology 142, 1574-1585, (1993).
[31] Roggers, R. A., Joglekar, M., Valenstein, J. S. & Trewyn, B. G. Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica. ACS applied materials & interfaces 6, 1675-1681, (2014).
[32] Kundu, P., Das, M., Tripathy, K. & Sahoo, S. K. Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson's Disease. ACS chemical neuroscience 7, 1658-1670, (2016).
[33] Chen, W., Su, H., Xu, Y. & Jin, C. In vitro gastrointestinal digestion promotes the protective effect of blackberry extract against acrylamide-induced oxidative stress. Scientific reports 7, 40514, (2017).
[34] Perricone, C., De Carolis, C. & Perricone, R. Glutathione: a key player in autoimmunity. Autoimmunity reviews 8, 697-701, (2009).
[35] Martinou, J.-C. & Youle, Richard J. Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial Dynamics. Developmental Cell 21, 92-101, (2011).
[36] Bock, F. J. & Tait, S. W. G. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol 21, 85-100, (2020).
[37] Maes, M.E., Schlamp, C.L., & Nickells, R.W., BAX to basics: How the BCL2 gene family controls the death of retinal ganglion cells. Progress in retinal and eye research. 57, 1-25 (2017).
[38] Zheng, J.H., Viacava Follis, A., Kriwacki, R.W., & Moldoveanu, T., Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J, 283(14), 2690-2700 (2016).
[39] Skommer, J., Brittain, T. & Raychaudhuri, S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis 15, 1223-1233, (2010).
[40] Nicholson, D.W. et al, Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376, 37-43. (1995).
[41] Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9, 231-241, (2008).
[42] Huang, R. Q. et al. Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. Journal of biomedical science 14, 121-128, (2007).
[43] Fang, F. et al. Non-invasive approaches for drug delivery to the brain based on the receptor mediated transport. Materials science & engineering. C, Materials for biological applications 76, 1316-1327, (2017).
[44] MacParland, S. A. et al. Phenotype Determines Nanoparticle Uptake by Human Macrophages from Liver and Blood. ACS nano 11, 2428-2443, (2017).
[45] Huang, X. et al. The Shape Effect of Mesoporous Silica Nanoparticles on Biodistribution, Clearance, and Biocompatibility in Vivo. ACS nano 5, 5390-5399, (2011).
[46] Blandini, F. & Armentero, M.-T. Animal models of Parkinson’s disease. The FEBS Journal 279, 1156-1166, (2012).
[47] Li, Y. et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 106, 1285-1290, (2009).
[48] Javitch, J. A., D'Amato, R. J., Strittmatter, S. M. & Snyder, S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the United States of America 82, 2173-2177, (1985).
[49] Butler, K. S. et al. Protocells: Modular Mesoporous Silica Nanoparticle-Supported Lipid Bilayers for Drug Delivery. Small (Weinheim an der Bergstrasse, Germany) 12, 2173-2185, (2016).
[50] Chen, Y., Chen, H. & Shi, J. In Vivo Bio-Safety Evaluations and Diagnostic/Therapeutic Applications of Chemically Designed Mesoporous Silica Nanoparticles. Advanced Materials 25, 3144-3176, (2013).
[51] Yang, J. et al. Rapid-releasing of HI-6 via brain-targeted mesoporous silica nanoparticles for nerve agent detoxification. Nanoscale 8, 9537-9547, (2016).
[52] Huajun, J. et al. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta 1842(8), 1282-1294, (2014).
[53] Zhohui, L., et al. Curcumin protects against A53T alpha-synuclein-induced toxicity in a PC12 inducible cell model for Parkinsonism. Pharmacological research 63(5), 439-444, (2011).
[54] Shi, Y.-l., Benzie, I. F. F. & Buswell, J. A. L-DOPA oxidation products prevent H2O2-induced oxidative damage to cellular DNA. Life Sci 71, 3047-3057, (2002).
[55] Zhai, H., et al, Construction of a Glutathione-Responsive and Silica-Based Nanocomposite for Controlled Release of Chelator Dimercaptosuccinic Acid. International journal of molecular sciences. 19(12), E3790 (2018).
[56] Kim, M. H. et al. Facile synthesis of monodispersed mesoporous silica nanoparticles with ultralarge pores and their application in gene delivery. ACS nano 5, 3568-3576, (2011).
[57] Meng, H. et al. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS nano 9, 3540-3557, (2015).
[58] Zhang, J., et al, Cell death induced by α-terthienyl via reactive oxygen species-mediated mitochondrial dysfunction and oxidative stress in the midgut of Aedes aegypti larvae. Free Radic Biol Med. 137, 87-98 (2019).
[59] Mytilineou, C., Walker, R.H., JnoBaptiste, R., & Olanow, C.W., Levodopa Is Toxic to Dopamine Neurons in an in Vitro but Not an in Vivo Model of Oxidative Stress. Journal of Pharmacology and Experimental Therapeutics. 304, 792 (2003).
[60] Wang, X.-S. et al. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson’s disease: a systematic experiment literatures review. BMC Complement Altern Med 17, 412, (2017).